Cover Image
Market Research Report
Product code 

Metabolomics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Published: | Mordor Intelligence Pvt Ltd | 116 Pages | Delivery time: 2-3 business days


Back to Top
Metabolomics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)
Published: January 17, 2022
Mordor Intelligence Pvt Ltd
Content info: 116 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The metabolomics market is projected to register a CAGR 5.8% during the forecast period.

The high growth rate for Metabolomics is primarily due to its high demand in scientific communities for better analysis of diseases, biological processes, and growing applications in healthcare. There are a growing number of research universities collaborating with companies in developed markets, which use a combination of separation and detection techniques, such as Gas chromatography-mass spectrometry (GC-MS), for metabolite profiling of large sets of drugs for diagnosis and treatment of several chronic diseases, like diabetes mellitus. These researches are often recognized at the national level, and governments with private equity partners provide funds for more research toward drug discovery, biomarkers, and other related studies.

Key Market Trends

Biomarker and Drug Discovery Segment, under Application, is Expected to Hold the Highest Revenue

Metabolomics focuses mainly on profiling small-molecule metabolites (metabolic profiling), and differ from genomics and proteomics, which characterize the profiles of genes and proteins, respectively. Additionally, biomarkers are the objective and quantitatively-measurable indicators of biological or pathogenic processes. Both metabolomics and biomarkers are progressively used in drug discovery and development, managing disease progression, especially for personalized or precision medicine. Metabolomics and biomarkers are likely to advance drug development and personalized therapy in the future, mainly in highly demanding disease areas, such as cardiovascular and metabolic diseases, cancer, mental health, and other infectious diseases. The increasing challenges faced by the pharmaceutical industry, such as dwindling discovery pipelines, limited budget sanctioned for a particular R&D, increasing regulatory control, significant gaps in the future drug markets, are expected to drive the growth of the market.

North America Dominates the Market and is Expected to do Same during the Forecast Period

North America is expected to dominate the market, over other regions, throughout the forecast period. Metabolomics has become a vital tool for studying metabolic processes, stratification of patients, as well as illuminating the fundamental metabolic alterations in disease onset, progression, or response to therapeutic intervention.

The presence of high per capita healthcare expenditure, increasing adoption rate of healthcare technology, well-established direct sales channel across the region, and a continuous boost to small and mid-sized metabolomics-oriented research communities and companies, globally, from the National Institutes of Health (NIH) program, help in the growth of metabolomics business.

In the United States, the pharmaceutical industry is one of the most research-intensive organizations. The industry is deeply invested in applying innovative solutions to enhance pipeline development to support improvements in patient care. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), In 2018, the United States firms conduct over half the world's R&D in pharmaceuticals. Approximately 79.6 billion was invested in biopharmaceutical research and development in the United States in 2018. Thus, owing to all the above-mentioned factors, the market is expected to witness high growth during the forecast period.

Competitive Landscape

The metabolomics market is moderately competitive and consists of several major players. In terms of the market share, few of the major players currently dominate the market. The major global companies, such as Thermofisher, Bruker Corporation, and Agilent Technologies, are increasing collaboration with educational societies and research communities, funding them for more research with combination, separation, and detection technique licenses. With the specific requirements to metabolite research, the HPLC and UPLC are increasingly preferred over other techniques for its most versatile separation method. Several pharmaceutical companies prefer research institutes for characterizing toxicological studies, to develop new drugs against infectious diseases. The technical advancements and combination with MS and NMR are being rapidly adopted, globally. These segments, thus, primarily drive the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 49784



  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Demand for Personalized Medicines
    • 4.2.2 High Investments by Public and Private Sectors in the Field of Metabolomics
    • 4.2.3 Rising Need for Early and Accurate Diagnosis of Diseases
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Tools and Instruments
    • 4.3.2 Lack of Skilled Professionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Metabolite Analysis
    • 5.1.1 Analytical Techniques
      • Separation Techniques
      • Liquid Chromatography
      • Gas Chromatography
      • Capillary Electrophoresis
      • Detection Techniques
      • Mass Spectrometry
      • Nuclear Magnetic Resonance Spectroscopy
      • Other Detection Techniques
    • 5.1.2 Bioinformatics Tools and Database
  • 5.2 By Application
    • 5.2.1 Biomarker and Drug Discovery
    • 5.2.2 Toxicology
    • 5.2.3 Nutrigenomics
    • 5.2.4 Personalized Medicine
    • 5.2.5 Other Applications
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • GCC
      • South Africa
      • Rest of Middle East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies
    • 6.1.2 Bio-Rad Laboratories Inc.
    • 6.1.3 Bruker Corporation
    • 6.1.4 Danaher Corporation (SCIEX)
    • 6.1.5 LECO Corporation
    • 6.1.6 Shimadzu Corporation
    • 6.1.7 Thermo Fisher Scientific
    • 6.1.8 Waters Corporation
    • 6.1.9 PerkinElmer Inc.
    • 6.1.10 Kore Technology Limited